Drug General Information (ID: DDI5KDXS2I)
Drug Name			Cytarabine		Drug Info		Smallpox (Vaccinia) Vaccine, Live		Drug Info
Drug Type		Small molecule				Vaccine
Therapeutic Class		Antineoplastics				Vaccine

Mechanism of Cytarabine-Smallpox (Vaccinia) Vaccine, Live Interaction (Severity Level: Major)
Antagonize the effect of vaccine/toxoid Click to Show/Hide Mechanism Graph
Drug Name		Cytarabine				Smallpox (Vaccinia) Vaccine, Live
Mechanism		Immunosuppressive effects				Vaccine or toxoid
Key Mechanism Factor 1
		Factor Name		Vaccine/toxoid
		Factor Description		The beneficial effects of the vaccine/toxinoid may be reduced, leading to a diminished or suboptimal immune response.
Mechanism Description		Antagonize the effect of Smallpox (Vaccinia) Vaccine, Live when combined with Cytarabine

Recommended Action
Management		Routine, nonemergency smallpox vaccination is contraindicated in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued for at least 3 months in most cases. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).

References
1	CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
2	Cerner Multum, Inc. "Australian Product Information.".
3	Product Information. Dryvax (smallpox vaccine). Wyeth-Ayerst Laboratories, Philadelphia, PA.